Drugs / YL211
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06384352 | May 2024 → Jun 2031 expected | cancer | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YL211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06384352 ↗ |
| Route | Intravenous | “Patients will be treated with YL211 intravenous (IV) infusion only.” NCT06384352 ↗ |